360,000 Shares in Genenta Science S.p.A. Unsponsored ADR $GNTA Bought by Eurizon Capital SGR S.p.A.

Eurizon Capital SGR S.p.A. acquired a new position in shares of Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 360,000 shares of the company’s stock, valued at approximately $536,000. Eurizon Capital SGR S.p.A. owned 1.88% of Genenta Science at the end of the most recent quarter.

Separately, Citadel Advisors LLC acquired a new stake in Genenta Science during the 3rd quarter worth $41,000. Institutional investors own 15.13% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genenta Science in a research note on Friday, March 27th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Genenta Science Stock Performance

GNTA stock opened at $2.11 on Thursday. The stock has a 50-day moving average price of $0.77 and a two-hundred day moving average price of $1.11. The company has a current ratio of 14.16, a quick ratio of 14.16 and a debt-to-equity ratio of 0.35. Genenta Science S.p.A. Unsponsored ADR has a 1 year low of $0.55 and a 1 year high of $10.00.

Genenta Science (NASDAQ:GNTA) last released its earnings results on Tuesday, March 31st. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.28.

About Genenta Science

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.